Form 8-K - Current report:
SEC Accession No. 0001193125-25-140873
Filing Date
2025-06-13
Accepted
2025-06-13 17:25:18
Documents
16
Period of Report
2025-06-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d31831d8k.htm   iXBRL 8-K 35890
2 EX-4.1 d31831dex41.htm EX-4.1 97594
3 EX-4.2 d31831dex42.htm EX-4.2 105623
4 EX-10.1 d31831dex101.htm EX-10.1 207535
5 EX-10.2 d31831dex102.htm EX-10.2 117140
  Complete submission text file 0001193125-25-140873.txt   827459

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA qncx-20250612.xsd EX-101.SCH 2853
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20250612_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20250612_pre.xml EX-101.PRE 11263
18 EXTRACTED XBRL INSTANCE DOCUMENT d31831d8k_htm.xml XML 3653
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

EIN.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 251047764
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)